Year
Summary Financials (Consolidated - million TL)
| 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022* | 2023* | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales Volume (m UC) | 1.058 | 1.131 | 1.152 | 1,189 | 1,238 | 1,315 | 1,207 | 1,184 | 1,376 | 1,577 | 1.535 |
| Türkiye Sales Volume (m UC) | 574 | 578 | 593 | 601 | 621 | 651 | 554 | 512 | 581 | 597 | 567 |
| International Sales Volume (m UC) | 484 | 553 | 559 | 588 | 617 | 665 | 654 | 672 | 795 | 979 | 968 |
| Sales Revenues | 5.186 | 5.985 | 6.724 | 7.050 | 8.521 | 10.623 | 12.008 | 14.391 | 21.930 | 93.190 | 101.042 |
| EBIT | 594 | 629 | 632 | 641 | 874 | 1.255 | 1.517 | 2.143 | 3.434 | 11.474 | 14.475 |
| EBIT Margin | 11,5% | 10,5% | 9,4% | 9,1% | 10,3% | 11,8% | 12,6% | 14,9% | 15,7% | 12,3% | 14,3% |
| EBITDA | 892 | 962 | 1.051 | 1.093 | 1.379 | 1.871 | 2.279 | 3.137 | 4.666 | 15.941 | 18.127 |
| EBITDA Margin | 17,2% | 16,1% | 15,6% | 15,5% | 16,2% | 17,6% | 19,0% | 21,8% | 21,3% | 17,1% | 17,9% |
| Net Profit | 247 | 315 | 117 | -28 | 238 | 327 | 966 | 1.233 | 2.271 | 13.877 | 20.580 |
| Net Profit Margin | 4,8% | 5,3% | 1,7% | -0,4% | 2,8% | 3,1% | 8,0% | 8,6% | 10,4% | 14,9% | 20,4% |
| EPS for 100 Shares** | 1,0 | 1,2 | 0,5 | -0,1 | 0,9 | 1,3 | 3,8 | 4,9 | 8,9 | 54,6 | 81,0 |
| Total Equity | 2.871 | 3.373 | 4.142 | 4.997 | 5.440 | 6.451 | 7.369 | 8.737 | 14.970 | 47.150 | 44.955 |
| Total Assets | 7.006 | 7.202 | 8.946 | 10.456 | 13.394 | 14.020 | 15.960 | 19.147 | 33.262 | 107.259 | 110.158 |
| Net Debt | 1.607 | 1.884 | 2.372 | 2.293 | 2.257 | 2.793 | 2.559 | 1.476 | 5.176 | 10.010 | 14.909 |
| Sales Volume |
Low-to-Mid-single-digit volume decline on a consolidated basis; |
| Net Sales Revenue | High 10s to Low 20s percentage FX-neutral NSR growth |
| EBIT Margin | Slight-decline-to-Flat vs previous year |
Note: The forward-looking guidance below is given on an organic basis and without any potential impact from the implementation of TAS 29 (Financial Reporting in Hyperinflationary Economies) and may change as per TAS 29. In order to provide a comparison with our previously shared guidance on Jan 8th 2024, we again release the below guidance based on historical figures (i.e., without TAS 29).
